Premier Wine Tasting and Auction Brought Acclaimed Napa Valley Vintners Together with Miami Philanthropists to Benefit Global Nonprofit CureDuchenne MIAMI, FL, April 16, 2025 – CureDuchenne, a global nonprofit committed to […]
Download PDF HERE CHAMPIONS SPONSORSHIP OPPORTUNITIES 2025
Wave Life Science Exon Skipping in Duchenne Wave Life Sciences: Update on 48-week Data from FORWARD-53 Exon Skipping Study: An update on Wave’s Phase 2 FORWARD-53 trial of WE-N531, Wave’s […]
Napa in Miami 2025 Auction Catalog Bid by proxy by emailing okairy@cureduchenne.org
AAV-microdystrophin gene therapy trial RegenXBio reported new interim data from 2 additional participants in the Phase 1/2 portion of the AFFINITY DUCHENNE trial of RGX-202, an AAV8-microdystrophin gene therapy. In [...]
Entrada trial skipping exon 45 CureDuchenne provided early funding to Entrada Therapeutics, who has announced that they received authorization in the United Kingdom (UK) to initiate a Phase 1/2 multiple […]
Sarepta Therapeutics has shared that a young man with Duchenne passed away following treatment with ELEVIDYS, an AAV-delivered micro-dystrophin gene therapy. Sarepta has shared that the individual suffered from acute […]
2025 MDA Conference Updates We’re at the 2025 MDA Clinical & Scientific Conference this week and are pleased to share research updates from companies presenting on the latest advancements in Duchenne muscular […]
CureDuchenne provided early funding to Dyne Therapeutics, and is pleased to share that Dyne has released new long-term data from the DELIVER trial in individuals amenable to skipping Exon 51. […]